Ultimovacs ASA (OSL:ULTI)
kr 7.45 -0.1 (-1.32%) Market Cap: 256.32 Mil Enterprise Value: 38.98 Mil PE Ratio: 0 PB Ratio: 0.99 GF Score: 30/100

Q4 2019 Ultimovacs ASA Earnings Call Transcript

Feb 14, 2020 / 08:00AM GMT
Release Date Price: kr58 (+4.69%)
Jónas Einarsson
Ultimovacs ASA - Chairman of the Board

Good morning, and welcome to the fourth quarter presentation from Ultimovacs. My name is Jónas Einarsson, I'm the Chairman of the Board of Ultimovacs. And the reason why I'm standing here today is that you've probably all seen that we issued a press release yesterday, that we have appointed Carlos de Sousa as the new CEO of Ultimovacs, and he is beginning at this year June 1.

We're very pleased that Carlos has accepted to take over from Ãyvind Arnesen. Carlos has a very broad and long experience in working in both biotech companies and in big pharma. And you can read more about his background in the press release. We're also very pleased that Ãyvind is willing to sign up to be on the (Inaudible) post until the June 1, and he will absolutely be the CEO of Ultimovacs until that date.

So very pleased to say that we will not lose Ãyvind out of our system. He will move a couple of sales down from his office today on June 1, and start working together with my colleague, and this team, and myself in Ultimovacs as the consultant. So we

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot